Dermatopathology, diagnostic tests and treatment safety
Histological patterns
Learn the algorithmic patterns and their differentials. Spongiosis = eczema. Psoriasiform = psoriasis (regular acanthosis, parakeratosis, Munro microabscesses, thinned suprapapillary plate). Lichenoid/interface = lichen planus, lupus, drug eruption. Granulomatous = sarcoid, tuberculosis, leprosy. Leucocytoclastic vasculitis = fibrinoid change with neutrophils. Adding the dominant inflammatory cell (eosinophils, plasma cells, neutrophils) narrows things further.
Immunofluorescence and special tests
Direct immunofluorescence: pemphigus vulgaris shows intercellular IgG ("chicken wire"); bullous pemphigoid shows linear IgG and C3 at the basement membrane; dermatitis herpetiformis shows granular IgA in dermal papillae. Indirect titres track pemphigus activity. KOH microscopy for hyphae and spores, Tzanck smear for herpes group, Wood's lamp for selected tinea and pigment disorders.
Patch testing
The gold standard for allergic contact dermatitis. A common standard-series protocol includes readings around day 2 and day 4/5, with additional or modified readings where indicated , the delayed reading is essential. Avoid testing on active dermatitis and remember that oral steroids and potent topical steroids at the test site suppress reactions.
Biopsy technique
Choose an early, untreated, fully developed lesion, include adequate tissue depth for the actual differential, such as subcutis when panniculitis is suspected, orient the specimen, and take multiple specimens when uncertain. Biopsy depth and method must preserve the tissue needed for diagnosis and staging. A superficial shave can be inadequate for an invasive melanocytic lesion or panniculitis, while a properly planned deep saucerization can be appropriate in selected melanocytic cases.
Traps
- Reading patch tests only at 48 hours and missing late positives.
- Accepting a "non-specific dermatitis" report after an inadequate superficial biopsy.
- Treating a negative KOH as proof there is no fungal infection.
- Correlating histology with a clinical history the pathologist never received.
Rule of thumb
Give the pathologist one sentence: site, duration, and your top two differentials , the same section looks different under different clinical questions.
Treatment mechanisms and patient selection
A drug's molecular target does not by itself establish that it is appropriate for a particular patient. IL-17-pathway treatment can be associated with inflammatory-bowel-disease concerns, and the precautions or contraindications differ among products and regulatory labels. Avoid calling every product in a class absolutely contraindicated under every authority. Oral JAK-inhibitor safety assessment includes cardiovascular, thrombotic, malignancy and infection risks under the applicable medicine and regulatory framework. That assessment is not identical to assigning every warning to every topical or systemic preparation.
Teratogenic medicines require explicit reproductive assessment and the applicable prevention process. Monitoring and cessation intervals depend on the actual medicine and current label rather than a common rule for all retinoids. Methotrexate used for inflammatory disease is not an ordinary daily regimen; prescribing frequency, monitoring and interactions are important safety checks. Azathioprine-related pharmacogenetic assessment can identify myelotoxicity risk, but a genotype result does not remove the need for clinical and laboratory monitoring. In all cases, distinguish a mechanism question from a complete prescription and connect benefit, risk, alternatives and the patient's circumstances.